Promise of Eli Lilly’s weight-loss drug for sleep apnea adds reason to own

Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the … Read more

WeightWatchers CEO just sent a memo to employees as stock crashes

Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected. … Read more

Weight loss ETFs may sit out obesity drug mania, experts say

There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two … Read more

Weight-loss drugs like Wegovy are meant for long-term use. Some patients want to stop

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a new dilemma: What happens if they stop taking them? Many worry, rightly, that they’ll regain weight and revert to old habits. In clinical trials, patients who paused the drugs put back on most of the … Read more

Mothers with obesity at greater risk of stillbirth: Canadian study – National

With obesity rates rising in Canada and globally, new research suggests there is a higher risk of stillbirth in mothers with obesity. Experts say early delivery could help minimize those risks. The study published in the Canadian Medical Association Journal (CMAJ) Monday found that maternal obesity on its own and along with other risk factors, … Read more

Study reveals over one billion now live with obesity globally

More than one billion people worldwide are now living with obesity, with rates among children increasing fourfold, a new report published by The Lancet has revealed. According to the study, obesity among adults globally has more than doubled since 1990 and has quadrupled among children and adolescents between five to 19 years of age. The … Read more

More than 1B people live with obesity globally, study shows. What about Canada?  – National

More than one billion people worldwide are grappling with obesity, with children in particular experiencing alarming increases in numbers, a new study shows. A global analysis published in the Lancet on Thursday found that obesity rates in children and adolescents across the world surged fourfold from 1990 to 2022. During this period, obesity rates more … Read more

More than a billion people worldwide are obese, WHO study finds

The findings, considered among the most authoritative of independent estimates, are based on data from more than 220 million people in more than 190 countries. The obesity rate is growing among children and adolescents faster than adults. Photo: Shutterstock While obesity rates are plateauing in many wealthier countries, they are rising rapidly elsewhere, Ezzati added. … Read more

The big decisions you’ll need to make once on new weight loss drugs

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right on … Read more

What to know about insurance coverage for weight loss drugs and costs

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to … Read more